Manufacturer

Pfizer Inc

Country

USA

Certificates

FDA

Document

0.29 MB

Registration Date	27 Jul 2016
Share

SUTENT ®

star_borderstar_borderstar_borderstar_borderstar_border

(0)

Medicine Pharmaceuticals Product Number : 0069-0770-38

Pancreatic Neuroendocrine Tumors

Drug Information

Generic

SUNITINIB MALATE

NDC Code

0069-0770-38

Drug Class

Multikinase inhibitors

Therapeutic Class

Antineoplastic

Dosage form

Capsule

Route of Administration

Oral

Therapeutic Area

1.Pancreatic neuroendocrine tumors

Indication

Sutent is indicated for Gastrointestinal Stromal Tumor (GIST) Advanced Renal Cell Carcinoma (RCC) Advanced Pancreatic Neuroendocrine Tumors (pNET)

Benefit

Sutent® is currently administrated orally as a capsule (and absorbed through the gastrointestinal tract), hence it poses no toxicity to the mouth cavity if integrated into the biotech start-up’s drug delivery platform (For about 9 years, SUTENT has been a widely used therapy in the treatment of advanced RCC and certain patients with GIST.* SUTENT may help slow the spread of cancer. SUTENT may also help shrink some tumors.)